Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Biograph Trinion positron emission tomography/computed tomography (PET/CT) system, which made its debut at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, including oncologic, cardiovascular, and neurologic imaging as well as theranostics, according to Siemens Healthineers, the manufacturer of the Biograph Trinion.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, according to Siemens Healthineers, the manufacturer of the newly FDA-cleared PET/CT system. (Image courtesy of Siemens Healthineers.)
The company emphasized that the device’s computer technology is located in the system gantry, allowing a more compact design that can be accommodated in an existing traditional PET/CT room. Siemens Healthineers added that the system’s smart power-save mode for powering down at night, can lead to a 46 percent reduction in energy costs.
“With the Biograph Trinion, Siemens Healthineers is proud to offer customers a high-performance PET/CT scanner that delivers the precision and speed needed for clinical demands,” said James Williams, PhD, head of Molecular Imaging at Siemens Healthineers. “This new system is designed to be user- and patient focused as well as a sustainable investment in terms of reduced installation and operational costs and easy, on-site scalability.”
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.